Recombinant Human HVEM-Fc/TNFRSF14 (Recombinant Human Herpesvirus Entry Mediator A Fc Chimera/TNFRSF14; rHuHVEM-Fc/TNFRSF14);重组人类疱疹病毒侵入介质A-Fc嵌合体/TNFRSF14
Fully biologically active when compared to standard. The biologically active as determined by its ability to inhibit TNF-beta -mediated cytotoxicity using murine L929 cells.
Lyophilized from a 0.2μm filtered concentrated solution in PBS, pH7.4, with 3% Trehalose.
Endotoxin
Less than 0.1EU/μg of rHuHVEM-Fc/TNFRSF14 as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Cytokine
Background
Herpesvirus entry mediator A (HVEM), also referred to as TNFRSF14, TR2 (TNF receptor-like molecule) and ATAR (another TRAF-associated receptor), is a type I transmembrane protein belonging to the TNF receptor superfamily. HVEM expression has been detected in peripheral blood T cells, B cells, monocytes and in various tissues enriched in lymphoid cells.